Christopher Counter
Duke University Medical Center, North Carolina, USA
Dr. Counter is the George Barth Geller Distinguished Professor of Pharmacology at Duke University and Associate Director of Basic Research in the Duke Cancer Institute. His laboratory focuses on how oncogenic mutations in RAS the proto-oncogenes initiate tumorigenesis”
Dr. Counter is the George Barth Geller Distinguished Professor of Pharmacology at Duke University and Associate Director of Basic Research in the Duke Cancer Institute. His laboratory focuses on how oncogenic mutations in RAS the proto-oncogenes initiate tumorigenesis”
